---
title: "TLX: H1 2026 revenue up 22% YoY to $477M, with EBITDA up 146% and net profit at $38M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296409205.md"
description: "Revenue grew 22% YoY to $477M in H1 2026, with EBITDA up 146% and net profit at $38M. Precision Medicine drove growth, supported by global expansion and new product launches, while R&D investment and manufacturing capacity increased to support future pipeline and regulatory milestones.Original document: Telix Pharmaceuticals Limited [TLX] Slides Release — Aug. 19 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-19T23:06:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296409205.md)
  - [en](https://longbridge.com/en/news/296409205.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296409205.md)
generator: "portal-rs"
---

# TLX: H1 2026 revenue up 22% YoY to $477M, with EBITDA up 146% and net profit at $38M

Revenue grew 22% YoY to $477M in H1 2026, with EBITDA up 146% and net profit at $38M. Precision Medicine drove growth, supported by global expansion and new product launches, while R&D investment and manufacturing capacity increased to support future pipeline and regulatory milestones.

Original document: Telix Pharmaceuticals Limited \[TLX\] Slides Release — Aug. 19 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [TLX.US](https://longbridge.com/en/quote/TLX.US.md)
- [TLX.AU](https://longbridge.com/en/quote/TLX.AU.md)

## Related News & Research

- [EGTX: Q2 2026 revenue up 23% YoY; U.S. Emcitate launch expected Q4 2026 pending FDA approval](https://longbridge.com/en/news/296636890.md)
- [LFS: Receivables and profit surged, with robust margins and strong capital returns amid macro pressures](https://longbridge.com/en/news/296541202.md)
- [BEWI: Q2 2026 delivered double-digit sales and EBITDA growth, with strong performance across all segments](https://longbridge.com/en/news/296303987.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [DE: 3Q 2026 saw sales and profit growth, but FY 2026 guidance signals industry headwinds](https://longbridge.com/en/news/296475895.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**